利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.013 秒)

    POLYMERS, AND THEIR USE AS GELS FOR ELECTROPHORESIS
    6.
    发明授权
    POLYMERS, AND THEIR USE AS GELS FOR ELECTROPHORESIS 失效
    聚合物，以及它们作为电泳的凝胶

    公开(公告)号：EP0318551B1

    公开(公告)日：1993-05-12

    申请号：EP88905199.1

    申请日：1988-06-10

    申请人： Kozulic, Branko, Dr. ,  MOSBACH, Klaus, Prof. Dr.

    发明人： Kozulic, Branko, Dr. ,  MOSBACH, Klaus, Prof. Dr.

    IPC分类号： C07K3/14 ,  G01N27/26 ,  C07C233/16 ,  C08F220/58

    CPC分类号： C08F220/58 ,  G01N27/44747 ,  Y10S524/916

    摘要： A novel synthesis of N-acryloyl-tris-(hydroxymethyl)aminomethane (NAT) is described. The polymerization kinetics and transparency of the poly(NAT) gels crosslinked by a crosslinker (CL) e.g. N,N'-methylenebisacrylamide (Bis), i.e. poly(NAT + Bis) polymer, are shown. Poly(NAT + Bis) gradient (4-24 %) gels were prepared and found to resolve native proteins according to their size. The exclusion limit of these gels is over 3 x 106 Da. This is more than threefold higher than the exclusion limit of the polyacrylamide gradient gel of the same concentration. Therefore poly(NAT + CL) gels are better than polyacrylamide gels for the resolution of large proteins. It was demonstrated that poly(NAT + CL)-polyacrylamide composite gels could be prepared. The poly(NAT + CL) gels were found to be advantageous also for isoelectric focussing in carrier ampholytes or immobilized pH gradients. Poly(NAT + CL) gels are also very good for separation of nucleic acids. The resolution is particularly good in the range between several hundred to 4-5000 base pairs. Under the optimized conditions, DNA molecules of more than 20 kbases can be perfectly resolved.

    Polyhydroxybenzyloxypropanolamines
    9.
    发明公开
    Polyhydroxybenzyloxypropanolamines 失效

    公开(公告)号：EP0373591A3

    公开(公告)日：1991-03-20

    申请号：EP89122921.3

    申请日：1989-12-12

    申请人： THE DU PONT MERCK PHARMACEUTICAL COMPANY

    发明人： Patil, Ghanshyam ,  Matier, William L. ,  Mai, Khuong H.X.

    IPC分类号： C07C217/28 ,  A61K31/135 ,  C07C233/16 ,  A61K31/16 ,  C07C233/62 ,  C07C233/78

    CPC分类号： C07C233/62 ,  C07C217/28 ,  C07C233/18 ,  C07C233/78

    摘要： Compounds of the present invention, are represented by the general formula
    wherein R₁ group which may be alkyl of from 1 to about 6 carbon atoms, alkenyl of from 2 to about 6 carbon atoms, alkynyl of from 2 to about 10 carbon atoms, alkoxy wherein the alkyl group contains from 1 to about 6 carbon atoms, halogen, acetamido, amino, nitro, alkylamino of from 1 to about 6 carbon atoms, hydroxy, hydroxyalkyl of from 1 to about 6 carbon atoms, cyano or arylalkoxy wherein the alkyl group contains from 1 to about 6 carbon atoms R₂, R₃ and R₄ are hydrogen or hydroxyl groups or the combination of either hydrogen or hydroxyl groups; W represents alkylene of from 1 to about 10 carbon atoms; and B represents -NHCOR₅, -NHCONR₅R₆, or -NHCOOR₅ wherein R₅ and R₆ may be the same or different and represent hydrogen, alkyl of from 1 to about 6 carbon atoms, alkoxyalkyl wherein the alkyl groups may be the same or different and contain from 1 to about 6 carbon atoms, cycloalkyl of from 3 to about 8 carbon atoms, alkenyl of from 2 to about 6 carbon atoms, alkynyl of from 2 to about 6 carbon atoms, phenyl which may be unsubstituted or substituted with alkyl of 1 to 6 carbon atoms; furanyl, thiophenyl, imidazole, oxazole or indole, aralkyl wherein the alkyl group contains from 1 to about 6 carbon atoms and the aryl group represents phenyl unsubstituted or substituted with alkyl of from 1 to about 6 carbon atoms, or R₅ and R₆ may together with N form a pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine ring and except that R₅ is not hydrogen when B is -NHCOOR₅; or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment or prophylaxis of cardiac disorders or in the treatment of glaucoma.

    摘要翻译： 本发明化合物由下列通式表示：其中R 1基团可以是1至约6个碳原子的烷基，2至约6个碳原子的链烯基，2至约10个碳原子的炔基， 烷基含有1至约6个碳原子的卤素，乙酰氨基，氨基，硝基，1至约6个碳原子的烷基氨基，羟基，1至约6个碳原子的羟基烷基，氰基或芳基烷氧基，其中烷基含有 1至约6个碳原子，R 2，R 3和R 4是氢或羟基或氢或羟基的组合; W表示1至约10个碳原子的亚烷基; 和B代表-NHCOR 5，-NHCONR 5 R 6或-NHCOOR 5，其中R 5和R 6可以相同或不同，代表氢，1至约6个碳原子的烷基，烷氧基烷基，其中烷基可以相同或不同，并且含有 1至约6个碳原子的环烷基，3至约8个碳原子的环烷基，2至约6个碳原子的烯基，2至约6个碳原子的炔基，可以未被取代或被1至6个 碳原子; 呋喃基，噻吩基，咪唑，恶唑或吲哚，其中烷基含有1至约6个碳原子的芳烷基和芳基表示未被取代或被1至约6个碳原子的烷基取代的苯基，或者R 5和R 6可以与 N形成吡咯烷，哌啶，哌嗪，吗啉或硫代吗啉环，并且当B是-NHCOOR 5时R 5不是氢; 或其药学上可接受的盐。 该化合物可用于治疗或预防心脏疾病或治疗青光眼。